dihexa derived from angiotensin iv Dihexa | | 1401708-83-5 |

Phase 1 study dosing: Doses tested: 100 mcg to 1000 mcg daily Route: subcutaneous injection Results: dose-proportional effects on fat loss Safety: all doses well tolerated Phase 2 study dosing: Doses tested: 300 mcg to 600 mcg daily Route: once- or twice-daily subcutaneous injection Duration: 12 weeks typical Results: significant fat loss at all doses, with 500600 mcg showing the best efficacy Research Dosage Guidelines Based on available clinical data, research protocols generally consider the following ranges

Fibroblast activation

Q: Do you offer bulk or long-term supply

Easy Nasal Spray Delivery: Ensures quick absorption and systemic action, making research straightforward and efficient

Ct values generated from the qPCR were plotted to produce standard curves (supplementary data), which were then used to calculate the total telomere length in kb for all samples